All Research Groups
Cytoskeletal and survival signaling
John Eriksson
john.eriksson[at]abo.fi
Turku Bioscience Centre &
Cell Biology, Faculty of Science and Engineering,
Åbo Akademi University
Cytoskeletal and survival signaling
Atomic-force microscopy, Basic research, Biochemistry, Cancer, Diabetes, Diagnostics, Electron microscopy, High throughput imaging, Imaging, In Vitro Diagnostics, Metabolic diseases, Molecular Biology, Molecular Cell Biology, Nanoparticles, Natural Compounds, Natural products, Physiology, Proteomics, Receptor, Signaling, Super-resolution imaging, Target discovery
Organic electronics
Ronald Österbacka
ronald.osterbacka[at]abo.fi
Laboratory of Physics,
Åbo Akademi University
Basic research, Physics
Alzheimers’s disease associated with metabolic diseases / Rare diseases
Ullamari Pesonen
ullamari.pesonen[at]utu.fi
Institute of Biomedicine,
University of Turku
Basic research, Biomarker, Biomedicine, Disease models, Drug target, Inherited diseases, Metabolic diseases, Neurological disorders, Personalized medicine, Pharmacology, Target discovery
Novel multitargeting therapies for neurodegenerative diseases
Timo Myöhänen
timo.myohanen[at]utu.fi
Institute of Biomedicine,
University of Turku
PREP in Neurodegenerative Disorders (Helsinki-group page)
Ageing-related diseases, Assay development, Basic research, Biomedicine, Diagnostics, Disease models, Drug target, Imaging software, In Vitro Diagnostics, In Vivo Diagnostics, MALS or SEC-MALS, Medicinal chemistry, Molecular Biology, Molecular modelling, Neurological disorders, PET, Pharmacology, Signaling, Target discovery
Recombinant antibodies and other bioaffinity molecules
Urpo Lamminmäki
urplammi[at]utu.fi
Department of Life Technologies,
University of Turku
Antibodies, Assay development, Basic research, Biomarker, Biotechnology, Cancer, Combinatorial chemistry, Diagnostics, Drug target, Fluorescence spectroscopy, Hit to lead, In Vitro Diagnostics, Infection, Lead optimization, Metabolic diseases, Molecular Biology, Molecular modelling, Nanoparticles, Next-generation sequencing, Ovarian cancer, Point of care, Prostate cancer, Screening, Synthetic Biology, Target discovery
